Dr. Robert Kramer of Boston University, and former president of the International Society of Impotence Research. He was chairman of a committee of leading scientists and researchers who reviewed the field of pharmacological therapy in a report to the meeting.
He mentioned two upcoming new oral medications:
Apomorphine - This compound acts on receptors in the brain. An FDA application has been made to market an oral version of this well-known compound. This follows completion of a number of clinical studies involving a total of about 1,000 patients which show a 50% success rate in improving erection. The tablet is placed under the tongue. It is expected to be available in the US by the end of 2000.
IC351- This is a compound similar to Viagra, but with a slightly different mechanism. It may not have the "blue haze" effect on the eyes that sometimes occurs with sildenafil. It is presently undergoing clinical trials.
Other upcoming drugs include:
Melanotan II- The mechanism is similar to apomorphine. This compound has shown good results in animal studies, and has been tested in small numbers of patients. It is still in the research phase.
Trazodone- This is also a well- known compound. "However, scientific data are lacking, and it seems to have little effect", notes, Dr Kramer.
Phentolamine- This medication is used in some combination therapies. However, clinical studies in Germany found no significant difference from placebo. In a US trial, it was found to have a modest effect on mild to moderate impotence.
Yohimbine- Dr. Kramer said his committee did not consider the available data sufficient to evaluate this drug.
No comments:
Post a Comment